These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 7907570)
1. A loading-dose strategy for converting from oral to depot haloperidol. Ereshefsky L; Toney G; Saklad SR; Anderson C; Seidel D Hosp Community Psychiatry; 1993 Dec; 44(12):1155-61. PubMed ID: 7907570 [TBL] [Abstract][Full Text] [Related]
2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Citrome L; Jaffe A; Levine J Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267 [TBL] [Abstract][Full Text] [Related]
3. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571 [TBL] [Abstract][Full Text] [Related]
4. Haloperidol and reduced haloperidol plasma concentrations after a loading dose regimen with haloperidol decanoate. Jann MW; Wei FC; Lin HN; Piao-Chien C; Chang WH Prog Neuropsychopharmacol Biol Psychiatry; 1996 Jan; 20(1):73-86. PubMed ID: 8861178 [TBL] [Abstract][Full Text] [Related]
5. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses. Roose K Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558 [TBL] [Abstract][Full Text] [Related]
6. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. Glick ID; Marder SR J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952 [TBL] [Abstract][Full Text] [Related]
7. Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics. Huttunen MO; Tuhkanen H; Haavisto E; Nyholm R; Pitkänen M; Raitasuo V; Romanov M Psychiatr Serv; 1996 Jan; 47(1):83-5. PubMed ID: 8925352 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. De Cuyper H; Bollen J; van Praag HM; Verstraeten D Br J Psychiatry; 1986 May; 148():560-6. PubMed ID: 2877701 [TBL] [Abstract][Full Text] [Related]
10. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689 [TBL] [Abstract][Full Text] [Related]
11. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. Chouinard G; Annable L; Campbell W J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086 [TBL] [Abstract][Full Text] [Related]
12. Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder. Sajatovic M; Levin J; Ramirez LF; Hahn DY; Tatsuoka C; Bialko CS; Cassidy KA; Fuentes-Casiano E; Williams TD J Clin Psychiatry; 2013 Dec; 74(12):1249-55. PubMed ID: 24434094 [TBL] [Abstract][Full Text] [Related]
13. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. Chouinard G; Safadi G; Beauclair L J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017 [TBL] [Abstract][Full Text] [Related]
14. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Youssef HA Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308 [TBL] [Abstract][Full Text] [Related]
15. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Wistedt B; Koskinen T; Thelander S; Nerdrum T; Pedersen V; Mølbjerg C Acta Psychiatr Scand; 1991 Jul; 84(1):14-21. PubMed ID: 1681680 [TBL] [Abstract][Full Text] [Related]
16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560 [TBL] [Abstract][Full Text] [Related]
19. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292 [TBL] [Abstract][Full Text] [Related]
20. 12-month study of haloperidol decanoate in chronic schizophrenic patients. Gelders YG; Reyntijens AJ; Ash CW; Aerts TJ Int Pharmacopsychiatry; 1982; 17(4):247-54. PubMed ID: 7185769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]